Related Experiment Video
Updated: Feb 22, 2026
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
Frequent PD-L1 Expression in Malignant Melanomas of the Vulva
Banafsheh Saleh1, Jörg Kriegsmann, Stephan Falk
1Optipath Institute of Pathology, Frankfurt (B.S., S.F., S.A.) Center for Histology, Cytology and Molecular Diagnostics, Trier (J.K.), Germany.
Abstract:
Blockade of immune checkpoint pathways such as the programmed cell death protein 1 pathway (PD-1/PD-L1) is an emerging approach in the treatment of solid tumors. In malignant melanoma, the efficiacy of antibodies against PD-L1 has been shown to be associated with PD-L1 protein expression. To evaluate whether this approach may be of use in the rare cases of primary melanoma of the vulva, we have evaluated a series of 13 cases for PD-L1 expression as well as additional molecular alterations of KIT, NRAS, KRAS, and BRAF. PD-L1 expression was detected in 69% of cases and was not associated with any other molecular alteration, tumor stage or morphology. In conclusion, targeting PD-L1 by selective antibodies may be of benefit in the treatment of these uncommon tumors.
Insights
Targeting programmed cell death protein 1 ligand (PD-L1) may benefit primary vulvar melanoma. PD-L1 expression was detected in most cases, independent of other molecular changes.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Immune checkpoint blockade, particularly targeting the programmed cell death protein 1 pathway (PD-1/PD-L1), is a promising cancer treatment.
- PD-L1 expression is a known predictive biomarker for anti-PD-L1 therapy efficacy in malignant melanoma.
Purpose of the Study:
- To investigate PD-L1 expression and associated molecular alterations in primary vulvar melanoma.
- To assess the potential of PD-L1 blockade as a therapeutic strategy for this rare malignancy.
Main Methods:
- Retrospective analysis of 13 primary vulvar melanoma cases.
- Evaluation of PD-L1 protein expression via immunohistochemistry.
- Analysis of molecular alterations in KIT, NRAS, KRAS, and BRAF genes.
Main Results:
- PD-L1 expression was detected in 69% of the evaluated primary vulvar melanoma cases.
- PD-L1 expression did not correlate with tumor stage, morphology, or the analyzed molecular alterations (KIT, NRAS, KRAS, BRAF).
Conclusions:
- Targeting PD-L1 with selective antibodies may represent a viable therapeutic option for primary vulvar melanoma.
- Further research is warranted to confirm the efficacy of PD-L1 blockade in this rare cancer subset.
More Related Videos
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
Related Concept Videos
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
02:23Abnormal Proliferation